Nanoparticles for Advanced Drug Delivery Systems: Innovations, Applications, and Future Perspectives in Nanomedicine

Nanotechnology, first conceptualized by Richard Feynman in 1959, has revolutionized science and medicine by enabling precise manipulation at the nanoscale. Nanoparticles (NPs), defined as structures with at least one dimension below 100 nm, exhibit unique physicochemical properties that make them indispensable in biomedical applications, particularly in diagnostics and drug delivery. Their high surface-area-to-volume ratio, tunable surface chemistry, and ability to encapsulate therapeutic agents allow for enhanced pharmacokinetics, targeted tissue delivery, and reduced systemic toxicity. In oncology, RNA-conjugated nanoparticles enable selective drug release at tumor sites, minimizing off-target effects. Polymeric nanoparticles—such as liposomes, dendrimers, and silica-based carriers—improve drug solubility, stability, and bioavailability, optimizing therapeutic outcomes. Green nanotechnology further advances sustainability by employing plant-based synthesis methods, reducing environmental impact while maintaining efficacy. DNA nanotechnology represents another frontier, where programmable nanostructures facilitate precision medicine through gene correction and personalized therapies. Despite these advancements, challenges persist in regulatory compliance, safety, and ethical considerations. Ensuring nanoparticle biocompatibility, long-term toxicity profiles, and scalable manufacturing remains critical for clinical translation. Regulatory frameworks must evolve to address these concerns while fostering innovation. This review comprehensively examines nanoparticle synthesis, characterization techniques, and functional applications in drug delivery. It highlights breakthroughs in nanobiotechnology, including gene therapy and stimuli-responsive systems, while addressing barriers to commercialization. By integrating interdisciplinary research, nanotechnology continues to redefine medical paradigms, offering transformative solutions for cancer, neurodegenerative disorders, and infectious diseases. The future of nanomedicine lies in harmonizing innovation with sustainability, ensuring safe and equitable healthcare advancements.

Authors

Publication Details

Journal
BioMed and BioSci Advances
Published
2024-12-01
DOI
https://doi.org/10.69626/bba.2024.0003
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nanoparticles for Advanced Drug Delivery Systems: Innovations, Applications, and Future Perspectives in Nanomedicine

Salman Khan, Safdar Sidra, Swati Tyagi, G.G.H.A. Shadab et al.
BioMed and BioSci Advances
Nanoparticle-Based Drug Delivery
article

Nanoparticles for Advanced Drug Delivery Systems: Innovations, Applications, and Future Perspectives in Nanomedicine

Salman Khan, Safdar Sidra, Swati Tyagi, G.G.H.A. Shadab, Bushra Ahmad, Fozia Z. Haque, Amreen Fatima, Masood Saleem Mir, Nuzhat Parveen, Mohd. Aarim
article en

Abstract

Nanotechnology, first conceptualized by Richard Feynman in 1959, has revolutionized science and medicine by enabling precise manipulation at the nanoscale. Nanoparticles (NPs), defined as structures with at least one dimension below 100 nm, exhibit unique physicochemical properties that make them indispensable in biomedical applications, particularly in diagnostics and drug delivery. Their high surface-area-to-volume ratio, tunable surface chemistry, and ability to encapsulate therapeutic agents allow for enhanced pharmacokinetics, targeted tissue delivery, and reduced systemic toxicity. In oncology, RNA-conjugated nanoparticles enable selective drug release at tumor sites, minimizing off-target effects. Polymeric nanoparticles—such as liposomes, dendrimers, and silica-based carriers—improve drug solubility, stability, and bioavailability, optimizing therapeutic outcomes. Green nanotechnology further advances sustainability by employing plant-based synthesis methods, reducing environmental impact while maintaining efficacy. DNA nanotechnology represents another frontier, where programmable nanostructures facilitate precision medicine through gene correction and personalized therapies. Despite these advancements, challenges persist in regulatory compliance, safety, and ethical considerations. Ensuring nanoparticle biocompatibility, long-term toxicity profiles, and scalable manufacturing remains critical for clinical translation. Regulatory frameworks must evolve to address these concerns while fostering innovation. This review comprehensively examines nanoparticle synthesis, characterization techniques, and functional applications in drug delivery. It highlights breakthroughs in nanobiotechnology, including gene therapy and stimuli-responsive systems, while addressing barriers to commercialization. By integrating interdisciplinary research, nanotechnology continues to redefine medical paradigms, offering transformative solutions for cancer, neurodegenerative disorders, and infectious diseases. The future of nanomedicine lies in harmonizing innovation with sustainability, ensuring safe and equitable healthcare advancements.

BioMed and BioSci AdvancesVol. 01(01)
Openalex Percentile: Top 86%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.